Mysterious money before the announcement of the crazy sweep the goods in Heng Group red envelopes to send who

As a body of heavy warehouse stocks, Zhong Heng Group (600252. SH) is undoubtedly the super big bull stock in recent years.　　Since November 2008, the two-tier market in China-Heng Group has risen 10 times-fold in two-year time. November 6, the company issued a notice, the content of the company's holding subsidiary Wuzhou Pharmaceutical (holding 99.99%) and Shandong Step size Medicine Sales Limited (step Medicine) signed a paper distribution agreement, will be produced in Wuzhou pharmaceutical products in line with the national drug quality standards of the total size of the product by step medicine, which means, In the next two years, the sales revenue of the pharmaceutical sector of Zhong Heng Group is expected to grow exponentially.　　In this positive, November 8, 9th two trading days, the group all declared "one word" trading. But it is doubtful that, in the two trading days before the announcement of the company, there is a mysterious capital to sweep the goods first, two trading day to limit the amount of the report.　　And its turnover is enlarged to 1.286 billion yuan and 1.42 billion yuan respectively, and the previous three trading days accumulated turnover only 1.167 billion yuan. In this respect, a brokerage researcher said that such a large volume of turnover is obviously not the general small, but large funds in the rapid pull high positions.　　This can not exclude the company's significant good is suspected of early leaks. "Send a red envelope" market according to the exchange rules, the three consecutive trading days in the stock price rose more than 20% of the listed companies must issue stock trading abnormal fluctuation announcements.　　Coincidentally, the group chose in two trading after the announcement of major good news, just free from the issue of stock price notice. So the company is sending out red envelopes.　　"said the former securities broker.　　According to the company announced that Wuzhou Pharmaceutical and step-length medicine to sign the total distribution agreement, will be produced by the Wuzhou pharmaceutical products in line with the national drug quality standards of all the product to step into the total distribution of medicine, the performance period from December 1, 2010 to November 30, 2015, a total of five years. According to the agreement, if the agreement can be implemented, the pharmaceutical sector of the group in 2011 will achieve tax-containing sales revenue of about 2.3 billion yuan, 2012 will achieve tax-containing sales revenue of about 3 billion yuan, the next three years are increased every year.　　This not only a strong guarantee of the company's 2010 operating performance, and will be the company's operating performance over the next five years have a positive impact.　　Relevant data indicate that the total operating income of the group in 2009 is 712 million yuan, of which the pharmaceutical plate operating income of 520 million yuan, and in the first half of this year, the company's pharmaceutical sector sales revenue is only 367 million yuan. Up to now, the pharmaceutical business has become the company's performance of the "absolute main force."　　In 2009 and the first half of this year, the net profit of shareholders in listed companies was 126 million yuan and 135 million yuan respectively, of which the pharmaceutical sector contributed a net profit of up to 134 million yuan and 163 million yuan, accounting for the total net profit proportion of the company as high as 106% and 121%. 杨挺, an analyst with GF Securities, said the announcement locked the companyTo 2 years of sales, clear the growth trend of the company's sales.　　In addition, step medicine is also the domestic cardiovascular and cerebrovascular field of leading enterprises, this cooperation shows that the company's products in the industry has been widely recognized. "The company will not only experience a clear performance improvement in the future, it will also experience a rise in valuations."　　"杨挺 said.　　Guo Xin Securities analyst congratulate Ping Pigeon said, Wuzhou Pharmaceutical has a major thrombus-tong excellent product group, but marketing is its weak link, is currently in the high-speed growth of the core product thrombus through the use of the floor agent sales model, general medicine by the company's own sales but the improvement is not obvious. Previously, because the company has been taking the floor price agent sales model, there is a certain policy risk (such as the country may be to the "liquidity rate" to strengthen control), dealers are also very sensitive to product price factors (such as the third quarter because of the expected reform and Development Commission on the base Medicine price adjustment, dealers take the goods is not high, resulting in lower sales expectations,　　It also gives the market some qualms about whether the company's full-year goals can be achieved. and Thrombus pass to step after pharmacy as the total distributor, is expected to resolve the above risk factors.　　Up to now, the step-length pharmacy has more than million people, covering the country's powerful marketing network and team. "If the content of the agreement can be completed as expected, it means that with the marketing force of Step Medicine, the 2012-year sales of Thrombus is expected to reach 2.4 billion yuan (based on the factory floor price of the constant)."　　"Congratulate Ping Pigeon is expected.　　Wang Yawei sit on the mysterious funds by the introduction of a lot of money to lift the company before the stock price, and has already sneaked into it, to Wang Yawei as a representative of the Fund of course is happy to sit sedan chair.　　China-Heng Group's previous 2010 quarterly results report showed that, although the company's third quarterly performance is lower than expected, but the fund is still in pursuit of the main company. In the top ten circulating shareholders in the group, the Chinese department and the Guangdong Department's Fund became the biggest winner in the share price surge of China-Heng Group. As at the end of the three quarter, the top ten circulating shareholders in the group of 8 funds accumulated shareholding of 75.8925 million shares, the proportion of shares in the company's circulation shares of 17.75%.　　According to the closing price of November 9, the above-mentioned fund shares the current market value has reached 2.554 billion yuan, compared with the end of the three-quarter shareholding market value of 1.813 billion yuan increased significantly 742 million yuan. At the end of the report, Wang Yawei to the Chinese market select 1.76 million shares to 8.76 million shares, the company's top ten circulating shares of shareholders third, while the operation of the Chinese strategy select also in the three quarter, 580,000 shares to 5.38 million shares.　　In addition, the same brother Huaxia Dividend Fund also increased in the third quarter of 3.3499 million shares to 6.6997 million shares. However, in the third quarter, the most crazy to the number of the department of the Guangdong Poly-Feng Stock fund.　　The fund's three-quarter increase in 23.7239 million shares to 25.6654 million shares, a leap into the company's top ten circulating shareholders second, accounting for the proportion of the company's shares up to 6%, after the company's major shareholder Guangxi Zhong Heng Industrial Co., Ltd. In the third quarter, the Guangdong Department has two new funds, respectively, for the development of the broad market and GF Poly Rui, the final shareholding of 4.6777 million shares and 4.55 million shares respectively.　　And appeared in the top ten circulating shares of the company's only one insurer-Pacific life Insurance has also been overweight, its final shareholding also increased to 8.4999 million shares, in the third quarter to increase the warehouse 3.9301 million shares. It is worth mentioning that, in June this year, the group 12 million-share directional additional shares by the Chinese department and China's business department to the high Price, Huaxia Fund and Chinese fund Two fund companies to subscribe to 6 million shares respectively.　　The closing date for the restricted period is June 9, 2011. Among them, Wang Yawei the Chinese market selection and the Chinese strategy selected to subscribe to 2.12 million shares and 110,000 shares respectively, Huaxia Advantage growth subscription 2.6 million shares.　　In addition, the Chinese merchants flourishing growth and Chinese business leaders subscribed to 2.7 million shares and 2.6 million shares respectively. According to the release report published by China Heng Group, the two major fund companies subscribe to the unit price of 31.85 yuan/share, the final issue price ratio of 9.72 yuan issued a floor premium ratio of up to 227.67%. However, the cost of holding shares has been lowered to 15.93 yuan/share after the 10-2-to-8 removal from the middle of this year. As of 9th closed, only this part of the float surplus has reached 212.64 million yuan.